NCT03879057

Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid Tumors

Phase I Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surufatinib Combined With JS001 in Patients With Advanced Solid Tumors

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Peking University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, phase I study evaluating safety, tolerability, pharmacokinetics and efficacy of Surufatinib combined with the humanized anti-PD-1 antibody JS001 in patients with solid tumors.

Conditions

• Solid Tumor

Interventions

Type	Name	Description
DRUG	Surufatinib/humanized anti-PD-1 monoclonal antibody	humanized anti-PD-1 monoclonal antibody(JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with th combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activitation of lymphocytes and elimination of malignancy theoretically.

Timeline

• Start date: 2018-12-21
• Primary completion: 2020-12-20
• Completion: 2021-12-20
• First posted: 2019-03-18
• Last updated: 2019-10-01

Locations

1 site across 1 country: China